On October 22, 2024 XOMA Royalty Corporation (NASDAQ: XOMA) reported that it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience’s Biopharma Solutions business unit (Press release, Xoma, OCT 22, 2024, View Source [SID1234647313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This transaction further solidifies XOMA Royalty’s unique position in the biotech royalty space. We believe a growing base of commercial revenues coupled with a large and diverse early pipeline have the potential to deliver superior risk-adjusted returns for our shareholders," stated Brad Sitko, Chief Investment Officer at XOMA Royalty. "This transaction reinforces our commitment to a disciplined capital deployment strategy and showcases our ability to create bespoke royalty capital solutions to meet the unique needs of our partners."

Under the terms of the agreement, XOMA Royalty has acquired 50 percent of the economics related to Twist Bioscience’s 60-plus early-stage programs across 30 partners for a $15 million upfront payment.

Advisors

Gibson, Dunn & Crutcher LLP served as XOMA Royalty’s legal advisor.